Tormere Analytics
OverviewStock ResearchPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Pricing
Privacy PolicyTerms of Service

BIVI

$1.91-7.73%

BIOVIE INC.

Market Cap
$15M
Sector
Materials
Industry
Biotechnology
Beta
0.80
5yr monthly vs SPY
Price Chart
Loading…

Signals

Insider Velocity
26.4x
buying
Congress
—
recent trades
Short Volume
44%
W/W +4.4pp

Market & Alt Data

News
8
recent articles
Activist
13D
BIOVIE
Analyst Consensus
Strong Buy
8 analysts
Velocity Score
26.39x
Current Rate (90d)
258.67/mo
Baseline Rate
0.00/mo
Unique Buyers (90d)
4
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-08-282026-08-28KIM JOANNE WENDYChief Financial OfficerPurchase2,500$2.18$5K3,441View
2026-08-282026-08-28Chappell Amy SuzonDirectorPurchase727$2.16$2K727View
2026-08-282026-08-28Palumbo Joseph MChief Medical OfficerPurchase4,843$2.16$10K6,036View
2026-08-272026-08-28DO CUONG VDirector & President & CEOPurchase15.2K$2.08$32K16.1KView

Recent News

Dow closes sharply lower as oil surge fuels inflation fears
Yahoo Finance · 2026-09-08
BioVie Announces Update to Parkinson’s Phase 3 Development Program
Yahoo Finance · 2026-09-08
BioVie completes final patient visit in Phase 2 Long COVID trial
Yahoo Finance · 2026-08-31
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
Yahoo Finance · 2026-08-14

Informational purposes only, not investment advice.

BioVie stock sinks on Phase IIb Parkinson’s trial data
Yahoo Finance · 2026-08-07
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim
Yahoo Finance · 2026-08-06
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
Yahoo Finance · 2026-08-06
BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial
Yahoo Finance · 2026-08-05

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →